Search This Blog

Thursday, May 9, 2019

Healthcare Moving To Meet Patients Where They Are

Healthcare offerings are changing as providers and innovators seek to offer care in ways and settings that are convenient for the communities they serve.
“Part of the innovation is to get the patient to the most efficient point in the health system for the interaction they need to have today,” said Tom Andriola, vice president and chief information officer for the University of California System. “We’re not trying to build more hospitals. We’re trying to use the ones we have efficiently.”
A big part of what is driving healthcare to where it is most convenient for patients is new technology that allows telephone or video conference meetings, better scheduling, more streamlined service and even a team of experts on call to assist a practitioner in a rural location with a specific treatment.
But it is not all about technology. It is also about where appointments are being made, whether that is at a local pharmacy, in a clinic on a corporate campus or even in an individual’s home. These moves continue to bring more healthcare services out of the hospital setting, making better use of the beds there for more specialized or acute cases while more routine and preventive care moves to where it is more accessible for patients.
This in turn is shaping how medical buildings are designed and built. In California, where hospitals are working to meet strict seismic guidelines, there are advantages to having those buildings be as efficient as possible and move more services to other medical buildings that need to follow less-rigorous seismic requirements.
All of these topics were discussed at Bisnow’s recent all-day National Healthcare NorCal event at The Fairmont San Francisco. Panels discussed construction, design and consumer demand when it comes to accessing healthcare.
Healthcare providers are starting to re-examine the services that are needed within each community. The default is to think that each community needs a hospital and everything in it, but that is not really the case, said Dr. Denise Brown, Vituity’s chief strategy officer and executive vice president.
“You don’t actually need the hospital there. What you need is access to care that could happen somewhere else,” she said. If a patient needs expert care, it may make more sense to get that patient to somewhere like Stanford where experts are on hand, rather than whoever is responding in an ER situation locally, she said. “It’s not scarcity. It’s resource utilization in a different way.”
Once they get beyond thinking about hospital beds, providers can focus on how to take care of people in various settings, whether assisted living, psychiatric, telemedicine, even paramedic care that doesn’t necessitate taking the patient to the hospital, Brown said.
Such shifts lead to a redistribution of where hospital beds are needed, said Dr. George Tingwald, director of medical planning for Stanford University Medical Center. There may be fewer hospital beds needed in a particular community, but there is a shortage of beds at academic medical centers because of the specialized care received there.
Some of these shifts are leading to partnerships within the healthcare system, but also with outside partners. And some of that is supported by new advances in technology to provide remote treatment to patients.
It used to be that patients would have to come to a central Veterans Affairs campus for treatment, but that is not a pleasant experience if someone isn’t feeling well and has to drive five hours for a one-hour appointment, said Bonnie Graham, director for the San Francisco VA Health Care System.
There is also the challenge of staffing facilities in rural areas. So now the VA does a lot of appointments through phone and video connections and employs a “hub-and-spoke” model where smaller staffs in outlying areas can call on experts when there is a situation that demands a specialist’s input, such as the quick treatment needed for a stroke patient.
The VA is also working with college campuses with a large number of students who are veterans, providing care on campuses that integrates telehealth. Some localized care is going as far as bringing medical care to patient’s homes. The VA does a lot of home care.
To make these approaches work, the system needs “touchdown spots” in different parts of the state where nurses, who are going to homes with a laptop and doing care, can report in and do their paperwork without returning to a hospital or clinic. Graham said the VA is looking for partners to offer those sites.
Reaching patients at home isn’t a new concept, but there is a renewed interest, particularly when it comes to treating chronic conditions. Some of this can be done remotely through phone and email, while other providers are actually sending physicians to patient’s homes. Healthcare startup Heal allows in-home care of those with multiple chronic conditions, keeping them out of the hospital and ER, and helping to save insurer costs, Heal Medical Director Dr. Justin Zaghi said. Patients use an app to schedule appointments and doctors can refer to data from technology in the home for keeping an eye on measurements like blood pressure. This creates a better situation for the patient, who may have difficulty traveling to an outside appointment, but it also has benefits for the physician and insurer, since there are cost savings to not having office space for at-home doctors or not having a receptionist, but instead an app for booking appointments, Zaghi said.
Dr. Jordan Newmark, chair of the department of anesthesiology for Alameda Health System, mentioned a study out of Camden, New Jersey. That data-driven study found there was a huge reduction in costs and better outcomes when attention was paid to how to keep patients who accessed healthcare the most at home and healthier so they spent less time in the hospital.
“Finding ways of bringing resources to patients at home is important,” Newmark said. Often, with chronic conditions, the earlier the intervention, the better the outcome.
But that means people need care where they can get it and that is accessible despite the challenges of geography or time. Newmark mentioned he has patients who live 3 miles from the hospital, but can’t come in for an appointment because they can’t take the time away from managing children or get time off work.
“It’s access to care — meeting patients where they are and eliminating barriers to care,” he said.

Takeda: Application to FDA on ulcerative colitis med advances

  • An additional treatment modality would provide more flexibility in how patients receive vedolizumab, a biologic with a gut-selective mode of action
  • Vedolizumab set to be the only maintenance therapy to offer the option of intravenous or subcutaneous formulations for patients with ulcerative colitis
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for a subcutaneous (SC) formulation of vedolizumab for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC). Takeda proposes to make vedolizumab SC available in both pre-filled syringe and pen options.
“Acceptance of this regulatory submission for review brings us one step closer to our goal of better meeting the diverse needs of patients with ulcerative colitis in the U.S. The availability of a subcutaneous option for maintenance therapy with vedolizumab, in addition to the currently approved intravenous formulation, would provide physicians and patients with greater flexibility on route of administration, if approved,” said Uthra Sundaram, Senior Vice President, GI Business Unit, Takeda Pharmaceuticals U.S.A., Inc.

Magenta Updates Phase 2 Clinical Data on MGTA-456 Cell Therapy at AAN

— Six-month follow-up on patients with cerebral adrenoleukodystrophy (cALD) shows stable neurological function scores and early and persistent resolution of brain inflammation on MRI —
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company presented Phase 2 clinical data on its cell therapy, MGTA-456, at the annual meeting of the American Academy of Neurology in Philadelphia, Pennsylvania.
MGTA-456 is a cell therapy designed to provide a high dose of hematopoietic stem cells that are well-matched to the patient. The Company plans to enroll 12 patients in the ongoing Phase 2 study in inherited metabolic disorders, which include cALD, Hurler syndrome, metachromatic leukodystrophy and globoid cell leukodystrophy. The primary endpoint of the study is neutrophil engraftment after transplantation. The study is also collecting both short- and long-term disease-specific outcomes. Data from the first five evaluable patients treated in this study were highlighted in a poster presented by Ashish Gupta, MBBS, M.P.H., Assistant Professor, Department of Pediatrics and Division of Blood and Marrow Transplantation, University of Minnesota.
In a separate oral presentation today, Kevin Goncalves, Ph.D., Magenta Therapeutics, will highlight preclinical data demonstrating that the high stem cell dose in MGTA-456 accelerates and improves engraftment of human microglia in the brains of transplanted mice.
“We are very pleased to see signs of durable disease benefit in patients with cALD,” said John Davis, M.D., M.P.H., Chief Medical Officer, Magenta Therapeutics. “cALD is a rapidly progressive disease, and patients whose disease progresses quickly typically have poor long-term outcomes. The stable neurological function score and persistent decrease in brain inflammation in these two patients suggest that we have halted the inflammatory process associated with the disease which may provide long-term benefits. We look forward to providing an additional update from the study before the end of the year.”

Myriad details findings from EndoPredict study in early stage breast cancer

Myriad Genetics announced that the EndoPredict test identifies women with early-stage breast cancer who can safely forgo extended endocrine therapy five years after diagnosis. The newly published study assessed the ability of the EndoPredict test to predict early distant recurrence and late recurrence of breast cancer, according to nodal status. The analysis included 1,702 patients with early-stage ER-positive, HER2-negative breast cancer who received five years of endocrine therapy alone. Overall, 62.6 percent of patients had low EndoPredict scores. Women with low EndoPredict scores had a statistically significantly reduced risk of distant recurrence compared to those with high scores Importantly, EndoPredict was highly predictive of both early and late distant recurrence in both node-negative and node-positive women, Myriad said.
https://thefly.com/landingPageNews.php?id=2906623

Bristol Opdivo+radiation CheckMate-498 GBM trial missed OS endpoint

https://thefly.com/landingPageNews.php?id=2906580

Amneal Pharmaceuticals sees 2019 adjusted EPS 94c-$1.04, consensus 98c

Sees 2019 CapEx $100M.

Perrigo To Expand Into Adjacent Self-Care By Acquiring Ranir

– All cash transaction valued at $750 million, or approximately $685 million inclusive of cash tax benefits on a present value basis
– Ranir generated net sales of $287 million in calendar year 2018 and is anticipated to be growth and adjusted margin accretive to Perrigo’s consumer business
– Transaction expected to be approximately $0.10 accretive to 2019 adjusted EPS assuming an expected third quarter 2019 closing